Ipsen and Rhythm agree worldwide licence for two programmes for metabolic disorders

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
GE Opens First New Manufacturing Operation in Louisville, Ky...
Get set for Bupa Great Birmingham Run...
New Regional Aircraft Contracts and Support...
Harris Corporation's John Shipley Honored by U.S...
Farmers can use red diesel to help out during extreme weather...
Hogan Lovells' It's Not Just Peanuts Campaign Wins Legal Business...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Ipsen and Rhythm agree worldwide licence for two programmes for metabolic disorders
Biotechnology speciality care group Ipsen (Euronext:IPN) declared on Friday that it has entered into a licensing agreement with biotechnology company Rhythm Pharmaceuticals for Ipsen's proprietary peptide therapeutics targeting obesity, metabolic diseases and gastrointestinal disorders....

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search